NEW YORK, NY / ACCESSWIRE / April 5, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Curis, Inc. (“Curis” or the “Company) (NASDAQ:CRIS). Investors who purchased Curis securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/cris.
The investigation concerns whether Curis and certain of its officers and/or directors have violated federal securities laws.
On April 4, 2022, Curis announced “that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the Company’s TakeAim Leukemia Phase 1/2a study (NCT04278768)” for “orally-administered emavusertib (CA-4948) as monotherapy and in combination with azacitidine or venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).” According to the Company, “[w]ith the partial hold, the FDA is requesting additional data from the study, including data related to the death of a R/R AML patient who experienced, among several conditions, rhabdomyolysis, which has previously been identified as a dose-limiting toxicity of emavusertib[,]” and that “the FDA is requesting safety, efficacy, and other data, including data related to rhabdomyolysis and the Company’s determination of the Recommended Phase 2 Dose for emavusertib in this study.” Curis also advised that “[w]hile this partial hold does not affect the TakeAim Lymphoma study (NCT03328078), a Phase 1/2 open-label dose escalating clinical trial investigating emavusertib in patients with B-cell malignancies, the Company has decided to pause enrollment of new patients in that study as well, pending resolution of the partial clinical hold in the TakeAim Leukemia study.” On this news, Curis’ stock price fell $0.81 per share, or 33.33%, to close at $1.62 per share on April 4, 2022.
If you are aware of any facts relating to this investigation or purchasedCuris shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/cris. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com:
https://www.accesswire.com/696141/Bronstein-Gewirtz-Grossman-LLC-Notifies-Shareholders-of-Curis-Inc-CRIS-Investigation